医薬品の副作用調査の世界市場分析:臨床試験フェーズ別(前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験)、サービス提供者別(自宅内、契約委託)、セグメント予測、-2020...市場調査レポートについてご紹介

【英文タイトル】Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼
医薬品の副作用調査の世界市場分析:臨床試験フェーズ別(前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験)、サービス提供者別(自宅内、契約委託)、セグメント予測、-2020 (Code:GVIEW707656)

【レポートの概要(一部)】

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.
Contract outsourcing pharmacovigilance market is expected to grow at a lucrative rate of over 13.1% during the forecast period. Service flexibility and cost effectiveness associated with outsourcing are some key factors accounting for the segment’s lucrative growth.

Further key findings from the study suggest:

Pharmacovigilance services found the largest application in phase 4/IV clinical trial studies in 2013. Greater applicability and relevance are some factors accounting for the segment’s market position.
Contract outsourcing was the most revenue generating service provider segment in 2013. Minimization of upfront investments and reduction in fixed overhead costs are some factors expected to drive segment growth.
North America was the largest regional market, accounting for over 40.0% of the revenue in 2013. Presence of stringent healthcare regulations implemented by the U.S. FDA and high market penetration rates of electronic medical records are some factors responsible for its large share.
Asia Pacific is identified as the most lucrative market. Presence of a large pool of skilled labor and favorable business environments are some factors expected to drive regional market growth. Rapidly improving healthcare infrastructure in the emerging economies of India and China is also expected to provide new growth opportunities to the market participants.
Key players of this market include Quintiles Transnational Corporation, PAREXEL International, Clinquest Group BV, Pharmaceutical Product Development, Accenture Plc., Boehringer Ingelheim GmbH and Cognizant Technology Solutions
Providing customized end to end PV solutions & services and entering into strategic agreements are some key strategies adopted by these market players.
For the purpose of this study, Grand View Research has segmented the pharmacovigilance market on the basis of clinical trial phase, type of service provider and region:

Global Pharmacovigilance Clinical Trial Phase Outlook (Revenue, USD Million, 2012 – 2020)
• Pre Clinical
• Phase 0
• Phase 1/I
• Phase 2/II
• Phase 3/III
• Phase 4/IV
Global Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2012 – 2020)
• In- House
• Contract Outsourcing
Pharmacovigilance Regional Outlook (Revenue, USD Million, 2012 – 2020)
• North America
• Europe
• Asia Pacific
• RoW

.....

【日本語概要(※自動翻訳出力)】

※以下は、Microsoft社の翻訳システムを使用した自動翻訳結果です。レイアウト崩れと不自然な日本語表現が多く表示されます。

。。。(後略)

【レポートの目次(一部)】

Table of Contents

Chapter 1. Executive Summary
1.1. Pharmacovigilance– Industry Summary and Critical Success Factors (CSFs)
Chapter 2. Pharmacovigilance Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Pharmacovigilance – Market dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Pharmacovigilance – PESTEL Analysis
2.6. Pharmacovigilance Company Market Share Analysis, 2013
Chapter 3. Pharmacovigilance Clinical Trial Phase Outlook
3.1. Pharmacovigilance market share, by clinical trial phase, 2013 & 2020
3.2. Preclinical
3.2.1. Preclinical Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.3. Phase 0
3.3.1. Phase 0 Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.4. Phase I
3.4.1. Phase I Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.5. Phase II
3.5.1. Phase II Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.6. Phase III
3.6.1. Phase III Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.7. Phase IV
3.7.1. Phase IV Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 4. Pharmacovigilance Type of Service Provider Outlook
4.1. Pharmacovigilance market share, by type of service provider, 2013 & 2020
4.2. In- House
4.2.1. In-House Market Estimates and Forecasts, 2012 – 2020 (USD Million)
4.3. Contract Outsourcing
4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 5. Pharmacovigilance Regional Outlook
5.1. Pharmacovigilance market share by region, 2012 & 2020
5.2. North America
5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.2.2. Market Estimates and Forecasts, by Type of Service Provider
5.3. Europe
5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.3.2. Market Estimates and Forecasts, by Type of Service Provider
5.4. Asia Pacific
5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.4.2. Market Estimates and Forecasts, by Type of Service Provider
5.5. RoW
5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.5.2. Market Estimates and Forecasts, by Type of Service Provider
Chapter 6. Competitive Landscape
6.1 Accenture Plc.
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Boehringer Ingelheim GmbH
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.3.4 Strategic Initiatives
6.4 Clinquest Group B.V.
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Cognizant Technology Solutions Corporation
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Covance, Inc.
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 F. Hoffmann-La Roche Ltd
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.7.4 Strat
.....


【日本語目次(※自動翻訳出力)】

※以下は、Microsoft社の翻訳システムを使用した自動翻訳結果です。レイアウト崩れと不自然な日本語表現が多く表示されます。

。。。(後略)

【レポート販売概要】

■ タイトル:医薬品の副作用調査の世界市場分析:臨床試験フェーズ別(前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験)、サービス提供者別(自宅内、契約委託)、セグメント予測、-2020
■ 英文:Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020
■ 発行日:2015年2月15日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707656
■ 調査対象地域:グローバル

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼
医薬品の副作用調査の世界市場分析:臨床試験フェーズ別(前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験)、サービス提供者別(自宅内、契約委託)、セグメント予測、-2020 (Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020 / GVIEW707656)

※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。